Cargando…

A novel delayed lateral flow immunoassay for enhanced detection of SARS-CoV-2 spike antigen

A new detection strategy was developed to improve the sensitivity of a lateral flow immunoassay platform utilizing a delayed hydrophobic barrier fabricated with trimethylsilyl cellulose (TMSC). The SARS-CoV-2 spike receptor-binding domain (SARS-CoV-2 SP RBD) antigen was chosen as a model analyte to...

Descripción completa

Detalles Bibliográficos
Autores principales: Srithong, Pawanrat, Chaiyo, Sudkate, Pasomsub, Ekawat, Rengpipat, Sirirat, Chailapakul, Orawon, Praphairaksit, Narong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486763/
https://www.ncbi.nlm.nih.gov/pubmed/36125616
http://dx.doi.org/10.1007/s00604-022-05467-3
_version_ 1784792349188030464
author Srithong, Pawanrat
Chaiyo, Sudkate
Pasomsub, Ekawat
Rengpipat, Sirirat
Chailapakul, Orawon
Praphairaksit, Narong
author_facet Srithong, Pawanrat
Chaiyo, Sudkate
Pasomsub, Ekawat
Rengpipat, Sirirat
Chailapakul, Orawon
Praphairaksit, Narong
author_sort Srithong, Pawanrat
collection PubMed
description A new detection strategy was developed to improve the sensitivity of a lateral flow immunoassay platform utilizing a delayed hydrophobic barrier fabricated with trimethylsilyl cellulose (TMSC). The SARS-CoV-2 spike receptor-binding domain (SARS-CoV-2 SP RBD) antigen was chosen as a model analyte to demonstrate the superior detectability of this scheme. The novel device consists of 2 separate layers, so-called delayed lateral flow immunoassay (d-LFIA). The upper layer is intended for the analyte or sample flow path, where the test solution flows freely straight to the detection zone to bind with the primary antibody. The lower layer, located just underneath, is designed for the SARS-CoV-2 spike receptor-binding domain-conjugated gold nanoparticles (SARS-CoV-2 SP RBD-AuNPs) used for producing a colorimetric signal. This layer is fabricated with a TMSC barrier to time-delay the movement of SARS-CoV-2 SP RBD-AuNPs, thus allowing the antigen to bind with the primary antibody more efficiently. This platform exhibited a 2.6-fold enhancement in the sensitivity and 9.1-fold improvement in the limit of detection (LOD) as compared with the conventional LFIA. In addition, this d-LFIA device was satisfactorily applied to accurate screening of COVID-19 patients. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00604-022-05467-3.
format Online
Article
Text
id pubmed-9486763
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-94867632022-09-21 A novel delayed lateral flow immunoassay for enhanced detection of SARS-CoV-2 spike antigen Srithong, Pawanrat Chaiyo, Sudkate Pasomsub, Ekawat Rengpipat, Sirirat Chailapakul, Orawon Praphairaksit, Narong Mikrochim Acta Original Paper A new detection strategy was developed to improve the sensitivity of a lateral flow immunoassay platform utilizing a delayed hydrophobic barrier fabricated with trimethylsilyl cellulose (TMSC). The SARS-CoV-2 spike receptor-binding domain (SARS-CoV-2 SP RBD) antigen was chosen as a model analyte to demonstrate the superior detectability of this scheme. The novel device consists of 2 separate layers, so-called delayed lateral flow immunoassay (d-LFIA). The upper layer is intended for the analyte or sample flow path, where the test solution flows freely straight to the detection zone to bind with the primary antibody. The lower layer, located just underneath, is designed for the SARS-CoV-2 spike receptor-binding domain-conjugated gold nanoparticles (SARS-CoV-2 SP RBD-AuNPs) used for producing a colorimetric signal. This layer is fabricated with a TMSC barrier to time-delay the movement of SARS-CoV-2 SP RBD-AuNPs, thus allowing the antigen to bind with the primary antibody more efficiently. This platform exhibited a 2.6-fold enhancement in the sensitivity and 9.1-fold improvement in the limit of detection (LOD) as compared with the conventional LFIA. In addition, this d-LFIA device was satisfactorily applied to accurate screening of COVID-19 patients. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00604-022-05467-3. Springer Vienna 2022-09-20 2022 /pmc/articles/PMC9486763/ /pubmed/36125616 http://dx.doi.org/10.1007/s00604-022-05467-3 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Paper
Srithong, Pawanrat
Chaiyo, Sudkate
Pasomsub, Ekawat
Rengpipat, Sirirat
Chailapakul, Orawon
Praphairaksit, Narong
A novel delayed lateral flow immunoassay for enhanced detection of SARS-CoV-2 spike antigen
title A novel delayed lateral flow immunoassay for enhanced detection of SARS-CoV-2 spike antigen
title_full A novel delayed lateral flow immunoassay for enhanced detection of SARS-CoV-2 spike antigen
title_fullStr A novel delayed lateral flow immunoassay for enhanced detection of SARS-CoV-2 spike antigen
title_full_unstemmed A novel delayed lateral flow immunoassay for enhanced detection of SARS-CoV-2 spike antigen
title_short A novel delayed lateral flow immunoassay for enhanced detection of SARS-CoV-2 spike antigen
title_sort novel delayed lateral flow immunoassay for enhanced detection of sars-cov-2 spike antigen
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486763/
https://www.ncbi.nlm.nih.gov/pubmed/36125616
http://dx.doi.org/10.1007/s00604-022-05467-3
work_keys_str_mv AT srithongpawanrat anoveldelayedlateralflowimmunoassayforenhanceddetectionofsarscov2spikeantigen
AT chaiyosudkate anoveldelayedlateralflowimmunoassayforenhanceddetectionofsarscov2spikeantigen
AT pasomsubekawat anoveldelayedlateralflowimmunoassayforenhanceddetectionofsarscov2spikeantigen
AT rengpipatsirirat anoveldelayedlateralflowimmunoassayforenhanceddetectionofsarscov2spikeantigen
AT chailapakulorawon anoveldelayedlateralflowimmunoassayforenhanceddetectionofsarscov2spikeantigen
AT praphairaksitnarong anoveldelayedlateralflowimmunoassayforenhanceddetectionofsarscov2spikeantigen
AT srithongpawanrat noveldelayedlateralflowimmunoassayforenhanceddetectionofsarscov2spikeantigen
AT chaiyosudkate noveldelayedlateralflowimmunoassayforenhanceddetectionofsarscov2spikeantigen
AT pasomsubekawat noveldelayedlateralflowimmunoassayforenhanceddetectionofsarscov2spikeantigen
AT rengpipatsirirat noveldelayedlateralflowimmunoassayforenhanceddetectionofsarscov2spikeantigen
AT chailapakulorawon noveldelayedlateralflowimmunoassayforenhanceddetectionofsarscov2spikeantigen
AT praphairaksitnarong noveldelayedlateralflowimmunoassayforenhanceddetectionofsarscov2spikeantigen